Pre-approval Expanded Access of Retatrutide (LY3437943)

Conditions

• Obesity
• Obesity-related Complications

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Retatrutide — DRUG

Study Details

Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilogram per square meter \[kg/m²\] and at least two serious or life-threatening obesity-related complications who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine.

Key Dates

First listed

Jun 5, 2026

Status verified

Aug 2026

Central Contacts

• Physician Inquiries for Lilly Clinical Trial Information:
  1-800-LillyRx (1-800-545-5979)
  [email protected]

Find similar trials

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
• New Heart Imaging Techniques to Evaluate Possible Heart Disease
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland